Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.45 |
| ▸ | FYN | P06241 | 4/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340313 | 0.87 | RET (0.57) | RETFYNKDR | |
| SCHEMBL4333737 | 0.71 | RET (0.65) | RETFYNKDR | |
| SCHEMBL31500400 | 0.69 | FYN (0.55) | RETFYNPIM1 | |
| SCHEMBL4347267 | 0.69 | PIK3CG (0.57) | RETFYNKDR | |
| SCHEMBL14301975 | 0.69 | RET (0.73) | RETKDRPIM1 | |
| SCHEMBL4334417 | 0.68 | FYN (0.52) | RETFYNPIM1 | |
| SCHEMBL4333143 | 0.68 | RET (0.65) | RETFYNKDRPIM1 | |
| SCHEMBL14357172 | 0.68 | FYN (0.65) | RETFYNKDRPIM1 | |
| SCHEMBL4339347 | 0.68 | RET (0.56) | RETFYNKDR | |
| SCHEMBL4594311 | 0.67 | RET (0.85) | RETFYNKDRPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |